Huang Y, Hogle J M, Chow M
Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
J Virol. 2000 Sep;74(18):8757-61. doi: 10.1128/jvi.74.18.8757-8761.2000.
Poliovirus binding to its receptor (PVR) on the cell surface induces a conformational transition which generates an altered particle with a sedimentation value of 135S versus the 160S of the native virion. A number of lines of evidence suggest that the 135S particle is a cell entry intermediate. However, the low infection efficiencies of the 135S particle and the absence of detectable 135S particles during infection at 26 degrees C by the cold-adapted mutants argue against a role for the 135S particle during the cell entry process. We show here that binding of 135S-antibody complexes to the Fc receptor (CDw32) increases the infectivity of these particles by 2 to 3 orders of magnitude. Thus, the low efficiency of infection by 135S particles is due in part to the low binding affinity of these particles. In addition, we show that there is an additional stage in the entry process that is associated with RNA release. This stage occurs after formation of the 135S particle, is rate limiting during infection at 37 degrees C, but not at 26 degrees C, and is PVR independent. The data also demonstrate that during infection at 26 degrees C, the rate-limiting step is the PVR-mediated conversion of wild-type 160S particles to 135S particles. This suggests that during infection at 26 degrees C by the cold-adapted viruses, 135S particles are formed, but they fail to accumulate to detectable levels because the subsequent post-135S particle events occur at a significantly faster rate than the initial conversion of 160S to 135S particles. These data support a model in which the 135S particle is an intermediate during poliovirus entry.
脊髓灰质炎病毒与细胞表面的受体(PVR)结合会诱导构象转变,产生一种沉降值为135S的变体颗粒,而天然病毒体的沉降值为160S。大量证据表明,135S颗粒是细胞进入过程中的中间体。然而,135S颗粒的感染效率较低,并且在26℃下冷适应突变体感染期间未检测到可检测到的135S颗粒,这与135S颗粒在细胞进入过程中的作用相矛盾。我们在此表明,135S抗体复合物与Fc受体(CDw32)的结合使这些颗粒的感染性提高了2至3个数量级。因此,135S颗粒感染效率低部分是由于这些颗粒的结合亲和力低。此外,我们表明进入过程中还有一个与RNA释放相关的额外阶段。这个阶段发生在135S颗粒形成之后,在37℃感染期间是限速步骤,但在26℃时不是,并且与PVR无关。数据还表明,在26℃感染期间,限速步骤是PVR介导的野生型160S颗粒向135S颗粒的转化。这表明在冷适应病毒于26℃感染期间,会形成135S颗粒,但它们未能积累到可检测水平,因为135S颗粒之后的事件发生速度比160S向135S颗粒的初始转化速度快得多。这些数据支持了一种模型,即135S颗粒是脊髓灰质炎病毒进入过程中的中间体。